AZD0171

Phase 2Small molecule

AstraZeneca

AZD0171 is one of 53 small molecule programs targeting Solid Tumours. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid TumoursActive, not recruiting

Non-Small Cell Lung CancerRecruiting

Solid TumoursPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Recruiting

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

SSGJ-707

SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Phase 3

1 2

Uliledlimab

TTJ Biopharma Co., Ltd.

Phase 3

2 3

Second-Line Systemic Therapy

SSun Yat-sen University

Phase 3

1 4

AZD0171

AstraZeneca

Phase 2

1 5

Remeron

OOrganon and Co

Preclinical

1 6

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—7

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—8

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1 9

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Treatment

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Solid Tumours

NCT04999969

Q2 2030

Phase 2Recruiting

Non-Small Cell Lung Cancer

NCT05061550

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT05061550·630 enrolled

Solid Tumours1 trial

A Phase II Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumours

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT04999969·126 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for AZD0171. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AZD0171 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AZD0171. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AstraZeneca

AZD0171

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2030

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Solid Tumours1 trial

References

Drug Info

Quick Facts

Related News